International Conference on Cardiology and Cardiovascular Medicine
Tuesday 15 October 2024
Cardio Oncology Heart Failure & Cancer Link Unveiled #pencis #cardiolog...
Monday 14 October 2024
First wave of COVID-19 increased risk of heart attack, stroke up to three years later
Compared to people with no COVID-19 history, the study found those who developed COVID-19 early in the pandemic had double the risk for cardiovascular events, while those with severe cases had nearly four times the risk. The findings were published in the journal Arteriosclerosis, Thrombosis, and Vascular Biology.
“This study sheds new light on the potential long-term cardiovascular effects of COVID-19, a still-looming public health threat,” said David Goff, M.D., Ph.D., director for the Division of Cardiovascular Sciences at NIH’s National Heart, Lung, and Blood Institute (NHLBI), which largely funded the study. “These results, especially if confirmed by longer term follow-up, support efforts to identify effective heart disease prevention strategies for patients who’ve had severe COVID-19. But more studies are needed to demonstrate effectiveness.”
The study is also the first to show that increased risk of heart attack and stroke in patients with severe COVID-19 may have a genetic component involving blood type. Researchers found that hospitalization for COVID-19 more than doubled the risk of heart attack or stroke among patients with A, B, or AB blood types, but not in patients with O types, which seemed to be associated with a lower risk of severe COVID-19.
Scientists studied data from 10,000 people enrolled in the UK Biobank, a large biomedical database of European patients. Patients were ages 40 to 69 at the time of enrollment and included 8,000 who had tested positive for the COVID-19 virus and 2,000 who were hospitalized with severe COVID-19 between Feb. 1, 2020, and Dec. 31, 2020. None of the patients had been vaccinated, as vaccines were not available during that period.
The researchers compared the two COVID-19 subgroups to a group of nearly 218,000 people who did not have the condition. They then tracked the patients from the time of their COVID-19 diagnosis until the development of either heart attack, stroke, or death, up to nearly three years.
Accounting for patients who had pre-existing heart disease – about 11% in both groups – the researchers found that the risk of heart attack, stroke, and death was twice as high among all the COVID-19 patients and four times as high among those who had severe cases that required hospitalization, compared to those who had never been infected. The data further show that, within each of the three follow-up years, the risk of having a major cardiovascular event was still significantly elevated compared to the controls – in some cases, the researchers said, almost as high or even higher than having a known cardiovascular risk factor, such as Type 2 diabetes.
“Given that more than 1 billion people worldwide have already experienced COVID-19 infection, the implications for global heart health are significant,” said study leader Hooman Allayee, Ph.D., a professor of population and public health sciences at the University of Southern California Keck School of Medicine in Los Angeles. “The question now is whether or not severe COVID-19 should be considered another risk factor for cardiovascular disease, much like type 2 diabetes or peripheral artery disease, where treatment focused on cardiovascular disease prevention may be valuable.”
Allayee notes that the findings apply mainly to people who were infected early in the pandemic. It is unclear whether the risk of cardiovascular disease is persistent or may be persistent for people who have had severe COVID-19 more recently (from 2021 to the present).
Scientists state that the study was limited due to inclusion of patients from only the UK Biobank, a group that is mostly white. Whether the results will differ in a population with more racial and ethnic diversity is unclear and awaits further study. As the study participants were unvaccinated, future studies will be needed to determine whether vaccines influence cardiovascular risk. Studies on the connection between blood type and COVID-19 infection are also needed as the mechanism for the gene-virus interaction remains unclear.
Friday 11 October 2024
Unraveling Nesprin's Role in Dilated Cardiomyopathy#pencis#cardiology #N...
Unraveling Nesprin's Role in Dilated Cardiomyopathy
Wednesday 9 October 2024
This genetic association study is published in JAMA Dermatology.
“Our findings are consistent with genetic predictors of CVD associating with increased psoriasis risk with no reciprocal effect,” wrote the researchers of the study. “This suggests that pathways influencing CVD risk may also contribute to the causal biological pathways of psoriasis.”
Previous studies have identified a link between psoriasis and CVD. Psoriasis is an autoimmune disease, which is known to cause inflammation that is not only visibly on the skin, but with other parts of the body, including the heart.2 Researchers have identified several possible factors for this, including shared genetics and common inflammatory pathways.
In this study, the researchers aimed to determine the bidirectional relationship between genetic predictors of psoriasis with 2 major forms of CVD, coronary artery disease (CAD) and stroke, and the association between genetic predictors of CVD with 9 other IMIDs.1
The researchers utilized a 2-sample mendelian randomization (MR) approach to analyze summary-level data from large-scale genome-wide association studies, which included data on individuals of European descent and covered information on CAD, stroke, psoriasis, and 9 other IMIDs: acne, atopic dermatitis, asthma, celiac disease, Crohn disease, inflammatory bowel disease multiple sclerosis, rheumatoid arthritis, or ulcerative colitis.
The primary outcomes were the associations of genetic predictors of CAD and stroke with the risk of psoriasis and the other IMIDs using inverse-variance weighted estimation to determine the direction and strength of associations, while adjusting for potential confounding variables. Data were analyzed from January 2023 to May 2024.
The study included 181,249 cases and 1,165,690 controls with CAD; 110,182 cases and 1,503,898 controls with stroke; and 36,466 cases and 458,078 controls with psoriasis.
Contrary to prior assumptions, genetic predictors of psoriasis were not associated with an increased risk of CAD or stroke. However, in the reverse direction, genetic predictors of both CAD (OR, 1.07; 95% CI, 1.04-1.10; P = .003) and stroke (OR, 1.22; 95% CI, 1.05-1.41; P = .01) were significantly associated with a higher risk of developing psoriasis.
After adjusting for stroke, the association between CAD genetic predictors and psoriasis risk became nonsignificant, indicating a shared genetic effect between CAD and stroke that increases psoriasis risk. Importantly, no significant associations were found between cardiovascular genetic predictors and other common IMIDs, suggesting that this genetic link may be specific to psoriasis.
The researchers noted several limitations to the study, First, they were unable to empirically confirm that the second and third instrumental variable assumptions had not been violated, as this relied on the researchers’ judgment. Second, the bidirectional MR method may have led to bias estimates and reduced the power of the analysis. Third, although the study was able to identify moderate to large effects between CVD genetic predictors and other IMIDs, it may have been unable to identify smaller effect sizes.
Despite these limitations, the researchers believe the study suggests an association between genetic predictors of CVD with increased psoriasis risk with no reciprocal effect or associations with other IMIDs.
“This knowledge could help expedite biomarker discovery to improve cardiovascular risk prediction in the psoriasis population and lead to the development of novel therapeutic strategies that target common inflammatory pathways, potentially offering dual benefits in treating psoriasis and preventing CVD,” wrote the researchers.
More info : cardiology.pencis.com
Contact : cardiology@pencis.com
#CardiovascularHealth
#PsoriasisAwareness
#GeneticsAndHealth
#HeartDisease
#PsoriasisResearch
#ChronicInflammation
#AutoimmuneDisease
#GeneticResearch
#HeartAndSkin
Tuesday 8 October 2024
Sex Differences in Cardiovascular Pharmacology
The limited comprehension of pharmacological mechanisms in gender differences related to cardiovascular diseases underscores the need for more focused studies on women, aiming to optimize sex-specific therapy and enhance clinical outcomes for female CVD patients. The goal of this special issue is to focus on the investigation of sex differences in therapeutic responses to cardiovascular drugs, with the ultimate objective of improving clinical outcomes and refining personalized treatment approaches.
Specific Pharmacological Responses: Explore and elucidate the mechanisms underlying sex-specific responses to cardiovascular drugs.
Gender Dimorphism in Cardiovascular Pharmacology: Investigate and analyze sex dimorphism in the pathophysiology of cardiovascular diseases, highlighting its implications for drug responses.
Clinical Outcomes and Treatment Approaches: Examine the impact of sex differences on clinical outcomes in patients with cardiovascular diseases and animal models. Propose personalized treatment approaches based on gender-specific responses, aiming to enhance therapeutic efficacy and address the distinct needs of both male and female individuals affected by cardiovascular conditions.
Optimizing Sex-Specific Therapy: Focus on studies aiming to optimize therapy tailored to the sex of the individual, considering pharmacodynamic and pharmacokinetic factors.
Pharmacological Targets for Novel Drug Discovery: Identify and discuss potential pharmacological targets for novel drug discovery in the cardiovascular field, emphasizing sex-specific considerations.
Manuscript Types:
- Original Research Articles: Presenting novel findings and insights.
- Review Articles: Synthesizing existing knowledge and highlighting gaps.
- Clinical Studies: Investigating sex-specific responses in real-world scenarios.
- Pharmacological Mechanism Studies: Exploring the molecular basis of sex differences in drug responses.
- Perspective and Opinion Pieces: Offering unique viewpoints on the subject.
Contributors are encouraged to submit manuscripts that advance our understanding of sex differences in cardiovascular pharmacology, ultimately contributing to more effective and personalized treatment strategies.
Sunday 6 October 2024
Finerenone benefits in HFpEF may be greater in patients with recent worsening HF
Key takeaways:
- In patients with HF and LVEF 40% or greater, finerenone may have the most benefit in those with recent worsening HF.
- The trend may be due to a play of chance and more data are needed.
In patients with HF and left ventricular ejection fraction 40% or greater, the absolute risk reduction for total worsening HF events and CV death with finerenone vs. placebo was greatest in those with recent worsening HF, new data show.
However, no formal treatment interaction was observed in terms of relative risk reduction, according to a new analysis of patients from the FINEARTS-HF trial.
As Healio previously reported, in the main results of FINEARTS-HF, the nonsteroidal mineralocorticoid receptor antagonist finerenone (Kerendia, Bayer) reduced risk for CV death and worsening HF by 16% compared with placebo at 32 months. Akshay S. Desai, MD, MPH, FACC, FHFSA, cardiovascular medicine specialist and director of the cardiomyopathy and heart failure program at Brigham and Women’s Hospital and associate professor of medicine at Harvard Medical School, presented a prespecified analysis of the results stratified by recency of worsening HF during a virtual late-breaking clinical research session of the Heart Failure Society of America Annual Scientific Meeting. The in-person meeting was canceled due to Hurricane Helene.
Recent worsening HF
“FINEARTS-HF was unique among trials enrolling patients with HF and left ventricular EF 40% or more in that we deliberately targeted enrollment of patients with recent worsening HF events,” Desai told Healio. “Patients were eligible for enrollment during hospitalization for worsening HF or shortly after discharge from treatment for a worsening HF event, and enrollment of those without recent worsening HF was prospectively capped at about 50% of the total study enrollment. Accordingly, nearly half of the enrolled participants had experienced a recent worsening HF event (within 3 months of randomization) and about 12% were enrolled during a worsening HF event/hospitalization. These patients with worsening HF are known to be at high risk for subsequent morbidity and mortality and are a prime target for implementation of disease-modifying therapy. We therefore prespecified an analysis of the interaction between treatment and time from worsening HF to randomization as part of the study statistical analysis plan.”
The analysis, simultaneously published in the Journal of the American College of Cardiology, included 1,219 patients with a worsening HF event within 7 days before randomization, 2,028 patients with a worsening HF event between 7 days and 3 months before randomization and 2,754 patients who had a worsening HF event more than 3 months before randomization or no history of worsening HF events. The mean age was 72 years and the percentage of women ranged from 46% to 48%.
The primary outcome of CV death and total HF events (hospitalizations or urgent visits) favored the finerenone group in patients with a worsening HF event within 7 days before randomization (RR = 0.74; 95% CI, 0.57-0.95) and in patients with a worsening HF event between 7 days and 3 months (RR = 0.79; 95% CI, 0.64-0.97) but not in patients with a worsening HF event more than 3 months before randomization or no history of worsening HF events (RR = 0.99; 95% CI, 0.81-1.21), Desai said during the presentation.
However, he said, there was no formal treatment interaction (P for interaction = .07).
In a time-to-first event analysis, the treatment interaction was less pronounced (P for interaction = .46), he said.
Yet, the absolute risk reduction for the primary outcome conferred by finerenone did significantly vary by recency of worsening HF event (within 7 days, absolute RR per 100 patient-years = 7.8; 95% CI, 1.4-14.1; 7 days to 3 months, absolute RR per 100 patient-years = 4.6; 95% CI, 0.3-8.8; more than 3 months or no history, absolute RR per 100-patient years = 0.1; 95% CI, –2.2 to 2.4; P for trend = .01), he said.
High-risk population
Desai told Healio that “the lack of a compelling statistical interaction in these subgroups and the lack of consistency of this trend in other key secondary endpoints examined” mean that the researchers cannot rule out that the increased benefit of finerenone in patients with recent worsening HF is a chance finding, so more data from patients in the hospital with HF or recently discharged for it are necessary, and the REDEFINE-HF and CONFIRMATION-HF trials may provide that.
More info : cardiology.pencis.com
Contact : cardiology@pencis.com
#HeartFailure
#HFpEF
#Cardiology
#Finerenone
#ChronicKidneyDisease
#Type2Diabetes
#WorseningHeartFailure
#HeartHealth
#CardioRenal
Friday 4 October 2024
Revolutionary Insights Cardiac MRI Radiomics in Dilated Cardiomyopathy #...
Revolutionary Insights Cardiac MRI Radiomics in Dilated Cardiomyopathy
Cardio Oncology Heart Failure & Cancer Link Unveiled #pencis #cardiolog...
Cardio Oncology Heart Failure & Cancer Link Unveiled Cardio-oncology is an emerging field that explores the intersection between he...
-
Advances in the Treatment of Cardiovascular Disease Cardi...
-
Preventive Cardiology News: Preventive Cardiology Preventive cardiology is a subspecialty focused on ...